DexCom, Inc. (DXCM)
$
62.25
-3.84 (-6.17%)
Key metrics
Financial statements
Free cash flow per share
2.7856
Market cap
24.3 Billion
Price to sales ratio
5.2077
Debt to equity
0.5061
Current ratio
1.8825
Income quality
1.7227
Average inventory
616.6 Million
ROE
0.3244
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
DexCom, Inc. is a medical device company that specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems globally. The company earned an interest income of $0.00 showcasing its financial investments. Its products are utilized by individuals with diabetes and healthcare providers alike, featuring systems such as the DexCom G6, an integrated CGM system for effective diabetes management. The earnings before interest, taxes, depreciation, and amortization (EBITDA) is $1,163,600,000.00 a key indicator of the company's operational profitability. The company's product range also includes the Dexcom Real-Time API, which allows third-party developers to integrate real-time CGM data into digital health applications, and the Dexcom ONE, designed to eliminate the need for finger-stick blood glucose testing for diabetes treatment decisions. Additionally, DexCom Share provides remote monitoring capabilities. The company recorded an operating income of $911,800,000.00 reflecting its earnings from core operations, and the earnings per share (EPS) is reported at $2.14 indicating the company's profitability on a per-share basis. With a weighted average number of shares outstanding of 390,200,000.00 the company's shareholder base is highlighted, demonstrating its broad market engagement. The candidate for new offerings includes the next-generation Dexcom G7 CGM system, which is anticipated to enhance its product lineup. Furthermore, DexCom, Inc. has established a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop innovative blood-based or interstitial glucose monitoring products, marking an exciting expansion for the firm. In terms of market positioning, the stock is reasonably priced at $67.45 appealing to a broad range of investors. The stock exhibits a high average trading volume of 4,984,888.00 indicating strong liquidity in the market. With a mid-range market capitalization of $24,278,511,749.00 the company is a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Additionally, DexCom, Inc. belongs to the Healthcare sector, driving innovation and growth, which positions the company favorably for future advancements and investor interest.
Is DexCom, Inc. (DXCM) a good investment?
Investing in DexCom, Inc. (DXCM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is DexCom, Inc. (DXCM)'s stock forecast?
Analysts predict DexCom, Inc. stock to fluctuate between $54.11 (low) and $89.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is DexCom, Inc.'s market capitalization?
As of 2026-03-27, DexCom, Inc.'s market cap is $24,278,511,749, based on 390,016,253 outstanding shares.
How does DexCom, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., DexCom, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy DexCom, Inc. (DXCM) stock?
To buy DexCom, Inc. (DXCM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DXCM. Place an order (Market, Limit, etc.).
What is the best time to invest in DexCom, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has DexCom, Inc. stock ever split?
DexCom, Inc.'s last stock split was 4:1 on 2022-06-13.
How did DexCom, Inc. perform in the last earnings report?
Revenue: $4,662,000,000 | EPS: $2.14 | Growth: 46.58%.
Where can I find DexCom, Inc.'s investor relations reports?
Visit https://www.dexcom.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for DexCom, Inc.?
You can explore historical data from here
What is the all-time high and low for DexCom, Inc. stock?
All-time high: $164.86 (2021-11-18) | All-time low: $54.11 (2025-11-07).
What are the key trends affecting DexCom, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
businesswire.com
BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more details about future product features across its global portfolio at the upcoming 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11-14, 2026. “There is no better global stage than ATTD to showcase how we're.
fool.com
Intuitive Surgical is plenty able to navigate its current issues while capitalizing on growing demand for its devices. DexCom's total installed base is a fraction of its addressable market, giving it plenty of room for further growth.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
Dexcom has been outperforming its peers since our last coverage in December. I expect further progress this year, as the company's long-suffering gross margin profile is set to reverse course over the next fewyears with +200bps of improvements expected this year alone. DXCM's earnings multiple is pricier than other medical equipment peers, but if the degree of medium term earnings growth is taken into consideration, its valuations look cheap.
seekingalpha.com
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
fool.com
Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D.
See all news
